Dr. Anthony W. Tolcher, MD, is CEO, founder and Director of Clinical Research at NEXT Oncology in San Antonio, Texas, a phase I program with the mission to accelerate the development of the next breakthrough cure for cancer through high quality Phase I clinical and clinical pharmacology trials. In this function, Dr. Tolcher is coordinating and supervising clinical trials with novel targeted cancer therapies.

Dr. Tolcher is a board-certified Medical Oncologist with an MD degree from the University of British Columbia, Vancouver, Canada. Dr. Tolcher specialized in Internal Medicine and Medical Oncology in residency programs at the University of Toronto and again at the University of British Columbia, respectively, before engaging in oncology research at the National Cancer Institute (NCI), National Institutes of Health (NIH) in Bethesda. He has held a staff position at the British Columbia Cancer Agency in Vancouver before moving to the Institute for Drug Development, Cancer Therapy and Research Center University of Texas Health Science Center in San Antonio where he became Director of Clinical Research in 1999, a position he held for almost 10 years.

In 2007, Dr. Tolcher became co-founder and for a decade served as Director of Clinical Research at START (South Texas Accelerated Research Therapeutics) in San Antonio, TX, a global clinical trial organization enabling first-in-human clinical trials with innovative cancer drugs within a global network dedicated clinical trial sites in the U.S., Europe and in Asia. In this function, Dr. Tolcher has led and supervised many early-stage clinical trials with highly innovative, targeted cancer therapies, including antibody drug conjugates (ADCs). Dr. Tolcher is author or co-author of more than 130 peer-reviewed publications in the field of Medical and Clinical Oncology and an internationally renowned key opinion leader in the field of clinical validation of antibody drug conjugates.